Listed

Staar Surgical Co: Form 10-Q for the period ended Oct 1, 2021

Filed with the SEC on Nov 3, 2021 and accepted by EDGAR at Nov 3, 2021, 16:16 ET.

Share

Management's discussion and analysis

As filed, 25,987 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The matters addressed in this Item 2 that are not historical information constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Readers can recognize forward-looking statements by the use of words like “anticipate,” “estimate,” “expect,” “intend,” “plan,” “believe,” “will,” “should,” “forecast” and similar expressions in connection with any discussion of future operating or financial performance. In particular, these include statements about any of the following: any projections of or guidance as to earnings, revenue, sales, profit margins, expense rate, cash, effective tax rate, product mix, capital expense or any other financial items; the expected impact of the COVID-19 pandemic and related public health measures (including but not limited to their impact on sales, operations or clinical trials globally), the plans, strategies, and objectives of management for future operations or prospects for achieving such plans; statements regarding new, existing, or improved products, including but not limited to, expectations for success of new, existing, and improved products in the U.S. or international markets or government approval of a new or improved products (including the EVO family of lenses in the U.S. and the EVO Viva family of lenses for presbyopia internationally); commercialization of new or improved products; future economic conditions or size of market opportunities; expected costs of operations; statements of belief, including as to achieving 2021 and 2022 business plans; expected regulatory activities and approvals, product launches, and any statements of assumptions underlying any of the foregoing.

Although we believe that the expectations reflected in these forward-looking statements are reasonable, such statements are inherently subject to risks and we can give no assurance that our expectations will prove to be correct. Actual results could differ from those described in this report because of numerous factors, many of which are beyond our control. These factors include, without limitation, those described in in our Annual Report on Form 10-K in “Item 1A. Risk Factors” filed on February 24, 2021. We undertake no obligation to update these forward-looking statements after the date of this report to reflect future events or circumstances or to reflect actual outcomes.

The following discussion should be read in conjunction with the audited consolidated financial statements of STAAR, including the related notes, provided in this report.

Overview

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and companion delivery systems used to deliver the lenses into the eye. We are the world’s leading manufacturer of intraocular lenses for patients seeking refractive vision correction, and we also make lenses for use in surgery to treat cataracts. All the lenses we make are foldable, which allows the surgeon to insert them into the eye through a small incision during minimally invasive surgery. Refractive surgery is performed to treat the type of visual disorders that have traditionally been corrected using eyeglasses or contact lenses. We refer to our lenses used in refractive surgery as “implantable Collamer® lenses” or “ICLs.” The field of refractive surgery includes both lens-based procedures, using products like our ICL family of products, and laser-based procedures like LASIK. Successful refractive surgery can correct common vision disorders such as myopia, hyperopia, and astigmatism. Cataract surgery is a common outpatient procedure where the eye’s natural lens that has become cloudy with age is removed and replaced with an artificial lens called an intraocular lens (“IOL”) to restore the patient’s vision. STAAR employs a commercialization strategy that strives for sustainable profitable growth. Our goal is to position our refractive lenses throughout the world as primary and premium solutions for patients seeking visual freedom from wearing eyeglasses or contact lenses while achieving excellent visual acuity through refractive vision correction. We position our cataract IOL lenses used in surgery that treats cataracts based on quality and value.

Recent Developments

Orders for ICLs outstripped our supply of lenses in the quarter. With China being our largest market, our distributor’s inventory levels in China were drawn down to historically low levels to meet surgeon and patient demand. While we were able to meet 35% growth levels to the surgeon and patient community from our distributor inventory, we were only able to ship units equaling 19% growth to our distributor. COVID-related employment, production output and modest supply chain challenges impacted the quarter and resulted in a backlog of over 20,000 lenses at the end of the third quarter representing several million dollars of orders-in-house. Despite the challenges which we are addressing, we achieved global ICL unit growth up 29%, year over year, for the third quarter of 2021. ICL unit growth was up 44% in Japan, up 21% in South Korea, up 338% in India, up 25% in Germany, up 66% in the U.S. and up 32% in our hybrid distributor markets. In the U.S. our submission of clinical data for STAAR’s EVO ICL family of myopia lenses remains under customary interactive FDA review. While a formal written response from the FDA has now extended beyond the late October date implied by MDUFA IV performance goals for PMA supplements, we see nothing unusual related to our current process with the FDA at this time.

Critical Accounting Policies

This Management’s Discussion and Analysis of Financial Condition and Results of Income discusses and analyzes data in our unaudited Condensed Consolidated Financial Statements provided in this report, which we have prepared in accordance with U.S. generally accepted accounting principles. Preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Management bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Senior management has discussed the development, selection and disclosure of these estimates with the Audit Committee of our Board of Directors. Actual conditions may differ from our assumptions and actual results may differ from our estimates.

An accounting policy is deemed critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, if different estimates reasonably could have been used, or if changes in the estimate that are reasonably likely to occur could materially impact the financial statements. Management believes that there have been no significant changes during the nine months ended October 1, 2021 to the items that we disclosed as our critical accounting policies and estimates in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended January 1, 2021.

Results of Operations

The following table shows the percentage of our total sales represented by certain items reflected in our Condensed Consolidated Statements of Income for the periods indicated.

Percentage of Net Sales for Three Months October 1, 2021 October 2, 2020 Percentage of Net Sales for Nine Months October 1, 2021 October 2, 2020
Net sales 100.0% 100.0% 100.0% 100.0%
Cost of sales 22.4% 25.9% 22.1% 28.4%
Gross profit 77.6% 74.1% 77.9% 71.6%
General and administrative 18.9% 18.2% 19.0% 20.8%
Selling and marketing 31.1% 26.9% 29.3% 29.0%
Research and development 14.2% 18.6% 14.5% 19.5%
Total selling, general and administrative 64.2% 63.7% 62.8% 69.3%
Operating income 13.4% 10.4% 15.1% 2.3%
Total other income (expense), net (0.8)% 1.1% (0.9)% 0.7%
Income before income taxes 12.6% 11.5% 14.2% 3.0%
Provision for income taxes 2.3% 3.2% 2.8% 0.8%
Net income 10.3% 8.3% 11.4% 2.2%

Net Sales

Three Months Ended October 1, 2021 October 2, 2020 Percentage Change 2021 vs. 2020 Nine Months Ended October 1, 2021 October 2, 2020 Percentage Change 2021 vs. 2020
ICLs $54,153 $41,493 30.5% $159,889 $101,561 57.4%
Other product sales:
Cataract IOLs 2,525 3,325 (24.1)% 9,324 9,880 (5.6)%
Other surgical products 1,674 2,263 (26.0)% 2,258 6,021 (62.5)%
Total other product sales 4,199 5,588 (24.9)% 11,582 15,901 (27.2)%
Net sales $58,352 $47,081 23.9% $171,471 $117,462 46.0%

Net sales for the three months ended October 1, 2021 were $58.4 million, an increase of 24% from $47.1 million reported during the same period of 2020. The increase in net sales was due to increased ICL sales of $12.7 million, partially offset by a decrease in other product sales of $1.4 million. Changes in foreign currency unfavorably impacted net sales by $0.2 million.

Net sales for the nine months ended October 1, 2021 were $171.5 million, an increase of 46% from $117.5 million reported during the same period of 2020. The increase in net sales was due to increased ICL sales of $58.3 million, partially offset by a decrease in other product sales of $4.3 million. Changes in foreign currency favorably impacted net sales by $1.7 million.

Total ICL sales for the three months ended October 1, 2021 were $54.2 million, an increase of 31% from $41.5 million reported for the same period of 2020, with unit increase of 29%. The APAC region sales increased by 28%, with unit growth up 25%, due to sales growth in India up 348%, Japan up 42%, Korea up 23%, China up 22%, and other APAC Distributors up 18%. The Europe, Middle East, Africa and Latin America region sales increased 37% with unit increase of 51%, due to sales growth in Middle East and North Africa up 156%, Latin America up 46%, United Kingdom up 45%, Distributor Operations up 30% and Germany up 26% and Spain up 13%. The North America region sales increased 40%, with unit increase of 50%, due to sales growth in the U.S. up 50%. Changes in foreign currency unfavorably impacted ICL sales by $0.1 million for the three months ended October 1, 2021. ICL sales represented 92.8% and 88.1% of our total sales for the three months ended October 1, 2021 and October 2, 2020, respectively.

Total ICL sales for the nine months ended October 1, 2021 were $159.9 million, an increase of 57% from $101.6 million reported for the same period of 2020, with unit increase of 52%. The APAC region sales increased by 54%, with unit growth up 48%, due to sales growth in India up 158%, Japan up 66%, China up 51%, other APAC Distributors up 49%, and Korea up 36%. The Europe, Middle East, Africa and Latin America region sales increased 66% with unit increase of 68%, due to sales growth in the Middle East and North Africa up 117%, United Kingdom up 97%, Latin America up 81%, Distributor Operations up 62%, Spain up 59% and Germany up 51%. The North America region sales increased 82%, with unit increase of 94%, due to sales growth in the U.S. up 84% and Canada up 71%. Changes in foreign currency favorably impacted ICL sales by $1.6 million for the nine months ended October 1, 2021. ICL sales represented 93.2% and 86.5% of our total sales for the nine months ended October 1, 2021 and October 2, 2020, respectively.

Other product sales, including cataract IOLs were $4.2 million for the three months ended October 1, 2021, a decrease of 25% from $5.6 million reported for the same period of 2020, due to decreased sales of cataract IOLs and low margin injector part sales. Other product sales were $11.6 million for the nine months ended October 1, 2021, a decrease of 27% from $15.9 million reported for the same period of 2020, mainly due to product yield issues requiring rework related to preloaded injector parts manufactured on our behalf by a third-party vendor then sold by us to a third-party manufacturer for product they sell to their customers, as well as decreased cataract IOL sales. Changes in foreign currency unfavorably impacted other product sales by $0.1 million for the three October 1, 2021 and favorably impacted other product sales by $0.1 million for the nine months ended October 1, 2021. Other product sales represented 7.2% and 11.9% of our total sales for the three months ended October 1, 2021 and October 2, 2020, respectively, and represented 6.8% and 13.5% of our total sales for the nine months ended October 1, 2021 and October 2, 2020, respectively.

Gross Profit

Three Months Ended October 1, 2021 October 2, 2020 Percentage Change 2021 vs. 2020 Nine Months Ended October 1, 2021 October 2, 2020 Percentage Change 2021 vs. 2020
Gross profit $45,301 $34,871 29.9% $133,646 $84,061 59.0%
Gross margin 77.6% 74.1% 77.9% 71.6%

* Denotes change is greater than +100%.

Gross profit for the three months ended October 1, 2021 was $45.3 million, a 29.9% increase compared to the $34.9 million reported for the same period of 2020. Gross profit margin increased to 77.6% of revenue for the three months ended October 1, 2021 compared to 74.1% of revenue for the three months ended October 2, 2020, due to geographic sales mix and a decreased mix of injector part sales which carry a lower margin, partially offset by increased period costs associated with manufacturing projects for the three months ended October 1, 2021.

Gross profit for the nine months ended October 1, 2021 was $133.6 million, a 59.0% increase compared to the $84.1 million reported for the same period of 2020. Gross profit margin increased to 77.9% of revenue for the nine months ended October 1, 2021 compared to 71.6% of revenue for the nine months ended October 2, 2020, due to geographic sales mix, a decreased mix of injector part sales which carry a lower margin, and for the nine months ended October 2, 2020 there were $1.2 million period costs recorded as a result of COVID-19 and the resulting manufacturing pause from March 17, 2020 through April 27, 2020, partially offset by increased period costs associated with manufacturing projects for the nine months ended October 1, 2021.

General and Administrative Expense

Three Months Ended October 1, 2021 October 2, 2020 Percentage Change 2021 vs. 2020 Nine Months Ended October 1, 2021 October 2, 2020 Percentage Change 2021 vs. 2020
General and administrative expense $11,018 $8,589 28.3% $32,671 $24,406 33.9%
Percentage of sales 18.9% 18.2% 19.0% 20.8%

General and administrative expenses for the three months ended October 1, 2021 were $11.0 million, a 28.3% increase compared to the $8.6 million reported for the same period of 2020 due to due to increased bonus and stock-based compensation expenses, salary-related and payroll tax expenses and outside services. General and administrative expenses for the nine months ended October 1, 2021 were $32.7 million, a 33.9% increase compared to the $24.4 million reported for the same period of 2020 due to increased bonus and stock-based compensation expenses, salary-related and payroll tax expenses, outside services, corporate insurance and facilities costs.

Selling and Marketing Expense

Three Months Ended October 1, 2021 October 2, 2020 Percentage Change 2021 vs. 2020 Nine Months Ended October 1, 2021 October 2, 2020 Percentage Change 2021 vs. 2020
Selling and marketing expense $18,175 $12,649 43.7% $50,229 $34,003 47.7%
Percentage of sales 31.1% 26.9% 29.3% 29.0%

Selling and marketing expenses for the three months ended October 1, 2021 were $18.2 million, a 43.7% increase compared to the $12.6 million reported for the same period of 2020 due to increased advertising and promotional activities, salary-related and payroll tax expenses and trade shows expenses. Selling and marketing expenses for the nine months ended October 1, 2021 were $50.2 million, a 47.7% increase compared to the $34.0 million reported for the same period of 2020 due to advertising and promotional activities, salary-related and payroll tax expenses, commission expense, trade shows expense and bonus expenses.

Research and Development Expense

Three Months Ended October 1, 2021 October 2, 2020 Percentage Change 2021 vs. 2020 Nine Months Ended October 1, 2021 October 2, 2020 Percentage Change 2021 vs. 2020
Research and development expense $8,271 $8,751 (5.5)% $24,790 $22,960 8.0%
Percentage of sales 14.2% 18.6% 14.5% 19.5%

Research and development expenses for the three months ended October 1, 2021 were $8.3 million, a 5.5% decrease compared to the $8.8 million reported for the same period of 2020 due mainly to decreased clinical expenses associated with our EVO clinical trial. Research and development expenses for the nine months ended October 1, 2021 were $24.8 million, an 8.0% increase compared to the $23.0 million reported for the same period of 2020 due to increased bonus and stock-based compensation expenses and salary-related and payroll tax expenses, partially offset by decreased clinical expenses associated with our EVO clinical trial.

Other Income (Expense), Net

Three Months Ended October 1, 2021 October 2, 2020 Percentage Change 2021 vs. 2020 Nine Months Ended October 1, 2021 October 2, 2020 Percentage Change 2021 vs. 2020
Other income (expense), net $(461) $499 —* $(1,626) $781 —*
Percentage of sales (0.8)% 1.1% (0.9)% 0.7%

* Denotes change is greater than +100%.

Other expense, net for the three and nine months ended October 1, 2021 was $0.5 million and $1.6 million, respectively, compared to other income, net of $0.5 million and $0.8 million, respectively, reported for the same period of 2020 due primarily to increased foreign exchange losses (primarily euro).

Income Taxes

Three Months Ended October 1, 2021 October 2, 2020 Percentage Change 2021 vs. 2020 Nine Months Ended October 1, 2021 October 2, 2020 Percentage Change 2021 vs. 2020
Income tax provision $1,356 $1,489 (8.9)% $4,751 $887 —*

* Denotes change is greater than +100%.

We recorded income taxes of $1.4 million and $4.8 million for the three and nine months ended October 1, 2021, respectively, due to pre-tax income generated in certain foreign jurisdictions and, for the nine months ended October 1 2021, a recapture of our U.S. valuation allowance of $0.8 million as a result of increased tax deductions in the projection of taxable income used in our valuation assessment. The Company, from time to time may adjust the projections of taxable income as a result of current conditions. We recorded income taxes of $1.5 million for the three months ended October 2, 2020 due to pre-tax income generated in certain foreign jurisdictions, partially offset by a reversal of $0.2 million of its U.S. valuation allowance, as a result of an increase in foreign income and changes in the usage and release of certain deferred tax assets. We recorded an income taxes of $0.9 million for the nine months ended October 2, 2020 due to pre-tax income generated in certain foreign jurisdictions, offset by a release of our U.S. valuation allowance of $1.2 million, as a result of us revising our global forecasts in response to the impacts of COVID-19, and due to changes in the usage and release of certain deferred tax assets.

ASC 740 requires that a valuation allowance be established when it is more likely than not that all or a portion of a deferred tax asset may not be realizable. The ultimate realization of deferred tax assets is dependent upon future generation of income during the periods in which temporary differences representing net future deductible amounts become deductible. In evaluating our ability to recover our deferred tax assets, we consider among other things, projected future income, tax planning strategies and all other available evidence both positive and negative in making this assessment. The “incremental cash tax savings approach” is further described in Notes 1 and 10 of the Company’s fiscal 2020 Form 10-K. Under the incremental cash tax savings approach, our cumulative valuation allowance recorded was $38.4 million and $8.1 million for federal and state, respectively, at October 1, 2021, and $34.7 million and $7.4 million for federal and state, respectively, at January 1, 2021. Under the incremental cash tax savings approach, the valuation allowance recorded reflects the net operating losses and deferred tax assets which will not result in future cash tax savings and therefore provide no additional benefit. Total U.S. net deferred tax assets were $3.0 million and $3.9 million as of October 1, 2021 and January 1, 2021, respectively.

Liquidity and Capital Resources

We believe that current cash, cash equivalents and future cash flow from operating activities will be sufficient to meet our anticipated cash needs, including working capital needs, capital expenditures and contractual obligations for at least 12 months from the issuance date of the financial statements included in this quarterly report. Although we have experienced some delays in payments on accounts receivable as a result of the COVID-19 pandemic in the first half of 2020, this has improved since the third quarter of 2020 as our customers resume elective refractive surgery. We are unaware of any impairment of assets resulting from the COVID-19 pandemic. The Company did not apply for or require financing available under the Coronavirus Aid, Relief, and Economic Security “CARES” Act and does not expect to do so given the strength of our balance sheet. Our financial condition at October 1, 2021 and January 1, 2021 included the following (in millions):

October 1, 2021 January 1, 2021 2021 vs. 2020
Cash and cash equivalents $196.2 $152.5 $43.7
Current assets $263.9 $216.4 $47.5
Current liabilities 46.8 41.2 5.6
Working capital $217.1 $175.2 $41.9

We invest the net proceeds in short-term interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. Additionally, at October 1, 2021, we have a line of credit with a Japanese lender, in the amount of $1.3 million, with $3.2 million of availability. We expect to repay this credit facility in full upon maturity at November 21, 2021.

Net cash provided by operating activities was $35.5 million for the nine months ended October 1, 2021 compared to $1.4 million for the nine months ended October 2, 2020. Net cash provided by operating activities for the nine months ended October 1, 2021, consisted of $19.6 million in net income, $16.8 in non-cash items, offset by $0.9 million in working-capital changes. The increase in net cash provided by operating activities during the nine months ended October 1, 2021 was due to changes in net income of $17.0 million, net working capital of $12.9 million and non-cash items of $4.2 million.

Net cash used in investing activities was $9.0 million and $6.3 million for the nine months ended October 1, 2021 and October 2, 2020, respectively, and relate primarily to the acquisition of property, plant, and equipment, due to increased investments in manufacturing and leasehold improvements intending to satisfy growing demand for our products.

Net cash provided by financing activities was $18.0 million and $13.0 million for the nine months ended October 1, 2021 and October 2, 2020, respectively. Net cash provided by financing activities for the nine months ended October 1, 2021 consisted of $18.3 million of proceeds from the exercise of stock options, partially offset by $0.3 million repayment of finance lease obligations.

Credit Facilities and Commitments

Lines of Credit and Leases

See Notes 7 and 8 of the accompanying Condensed Consolidated Financial Statements.

Covenant Compliance

The Company is in compliance with the covenants of its credit facility as of October 1, 2021.

Employment Agreements

The Company’s Chief Executive Officer entered into an employment agreement with the Company, effective March 1, 2015. She and certain officers have as provisions of their agreements certain rights, including continuance of cash compensation and benefits, upon a “change in control,” which may include an acquisition of substantially all of its assets, or termination “without cause or for good reason” as defined in the employment agreements.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, as that term is defined in the rules of the SEC, that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

Market risk

As filed, 240 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

During the nine months ended October 1, 2021, there have been no material changes in the Company’s qualitative and quantitative market risk since the disclosure in the Company’s Annual Report on Form 10-K for the year ended January 1, 2021.

Controls and procedures

As filed, 3,363 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Disclosure Controls and Procedures

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our CEO and CFO, of the effectiveness of the design and operation of the disclosure controls and procedures of the Company. Based on that evaluation, our CEO and CFO concluded, as of the end of the period covered by this quarterly report on Form 10-Q, that our disclosure controls and procedures were effective. For purposes of this statement, the term “disclosure controls and procedures” means controls and other procedures of the Company that are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act (15 U.S.C. 78a et seq.) is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Our management, including the CEO and the CFO, do not expect that our disclosure controls and procedures or our internal control over financial reporting will necessarily prevent all fraud or material errors. An internal control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations on all internal control systems, our internal control system can provide only reasonable assurance of achieving its objectives and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of internal control is also based in part upon certain assumptions about the likelihood of future events, and can provide only reasonable, not absolute, assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in circumstances, or the degree of compliance with the policies and procedures may deteriorate.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended October 1, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 450 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Our short and long-term success is subject to many factors that are beyond our control. Investors and prospective investors should consider carefully information contained in this report and the risks and uncertainties described in “Part I—Item 1A—Risk Factors” of the Company’s Form 10-K for the fiscal year ended January 1, 2021. Such risks and uncertainties could materially adversely affect our business, financial condition or operating results.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-10-01. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2021-07-03 to 2021-10-01$58.4mus-gaap:Revenues
Revenue9 months2021-01-02 to 2021-10-01$171.5mus-gaap:Revenues
Cost of revenue3 months2021-07-03 to 2021-10-01$13.1mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2021-01-02 to 2021-10-01$37.8mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2021-07-03 to 2021-10-01$45.3mus-gaap:GrossProfit
Gross profit9 months2021-01-02 to 2021-10-01$133.6mus-gaap:GrossProfit
Research and development3 months2021-07-03 to 2021-10-01$8.3mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2021-01-02 to 2021-10-01$24.8mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2021-07-03 to 2021-10-01$37.5mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2021-01-02 to 2021-10-01$107.7mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2021-07-03 to 2021-10-01$7.8mus-gaap:OperatingIncomeLoss
Operating income9 months2021-01-02 to 2021-10-01$26.0mus-gaap:OperatingIncomeLoss
Income tax3 months2021-07-03 to 2021-10-01$1.4mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2021-01-02 to 2021-10-01$4.8mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2021-07-03 to 2021-10-01$6.0mus-gaap:NetIncomeLoss
Net income9 months2021-01-02 to 2021-10-01$19.6mus-gaap:NetIncomeLoss
Diluted EPS3 months2021-07-03 to 2021-10-01$0.12us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2021-01-02 to 2021-10-01$0.40us-gaap:EarningsPerShareDiluted
Basic EPS3 months2021-07-03 to 2021-10-01$0.13us-gaap:EarningsPerShareBasic
Basic EPS9 months2021-01-02 to 2021-10-01$0.42us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2021-07-03 to 2021-10-0149,592,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2021-01-02 to 2021-10-0149,448,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2021-01-02 to 2021-10-01$35.5mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2021-01-02 to 2021-10-01$9.0mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2021-10-01$196.2mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-10-01$263.9mus-gaap:AssetsCurrent
Total assetsAt period end2021-10-01$324.6mus-gaap:Assets
Current liabilitiesAt period end2021-10-01$46.8mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-10-01$75.5mus-gaap:Liabilities
Shareholders' equityAt period end2021-10-01$249.1mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001564590-21-053970. Last ingested by Listed: Nov 4, 2026, 17:00 ET. Listed shows no prices and gives no investment advice.